Chargement en cours...
Development of Intranasal Levothyroxine Powder Delivery for Hypothyroidism
Background: Hypothyroidism affects 3-5% of the general population with oral levothyroxine (LT4) being the predominant replacement therapy. However, significant proportion of hypothyroid patients are unable to absorb oral replacement leading to therapeutic failure and may require injectable thyroxine...
Enregistré dans:
| Publié dans: | J Endocr Soc |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8089816/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1689 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|